cisplatin + docetaxel + gemcitabine + vinorelbine

This is a combination chemotherapy regimen consisting of four drugs: cisplatin (a platinum-based agent), docetaxel (a taxane), gemcitabine (a nucleoside analog), and vinorelbine (a vinca alkaloid). While various combinations of these drugs have been studied in clinical trials for non-small cell lung cancer (NSCLC), the specific four-drug combination has limited documentation. Studies have compared docetaxel/gemcitabine versus vinorelbine/cisplatin combinations, and there is evidence of a triplet regimen using cisplatin, gemcitabine, and vinorelbine. These drugs work through different mechanisms to inhibit cancer cell division and growth.